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ABSTRACT
Electrochemotherapy is now in routine clinical use to treat cutaneous metastases of any histology, and
is listed in national and international guidelines for cutaneous metastases and primary skin cancer.
Electrochemotherapy is used by dermatologists, surgeons, and oncologists, and for different degrees
and manifestations of metastases to skin and primary skin tumours not amenable to surgery. This
treatment utilises electric pulses to permeabilize cell membranes in tumours, thus allowing a dramatic
increase of the cytotoxicity of anti-cancer agents. Response rates, often after only one treatment, are
very high across all tumour types. The most frequent indications are cutaneous metastases from malig-
nant melanoma and breast cancer. In 2006, standard operating procedures (SOPs) were written for this
novel technology, greatly facilitating introduction and dissemination of the therapy. Since then consid-
erable experience has been obtained treating a wider range of tumour histologies and increasing size
of tumours which was not originally thought possible. A pan-European expert panel drawn from a
range of disciplines from dermatology, general surgery, head and neck surgery, plastic surgery, and
oncology met to form a consensus opinion to update the SOPs based on the experience obtained.
This paper contains these updated recommendations for indications for electrochemotherapy, pre-
treatment information and evaluation, treatment choices, as well as follow-up.
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Introduction
Electrochemotherapy established its position as treatment for
cutaneous primary and secondary tumours [1–3]. The practice
of electrochemotherapy has developed through clinical trials
[4–13], the first standard operating procedure (SOP) for elec-
trochemotherapy of cutaneous tumours [14], as well as the
clinically certified electric pulse generator, to a point where
electrochemotherapy is routinely used.
The first SOP was prepared for the treatment of cutaneous
tumours of less than 3 cm in diameter [6,14]. Since electro-
chemotherapy worked extremely well for tumours in the
small diameter range, studies continued to investigate a role
for larger tumours such as large breast cancer chest wall
recurrences [9], and currently many centres are treating
patients with considerable tumour involvement of the skin.
Due to the expanded experience, and keeping in mind the
success of the first SOP to help align treatment between
centres, there was a need for revision in order to integrate
knowledge obtained from the centres routinely using electro-
chemotherapy, as well as to address the current and
expanded use of electrochemotherapy in a larger and more
diverse patient population.
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The simple and effective principle of electrochemotherapy
is based on a physical approach to permeabilize cells in the
tissue exposed to electric pulses, in order to enable increased
cellular uptake of hydrophilic chemotherapeutics that have
hampered transport through the cell membrane. By electro-
poration, bleomycin cytotoxicity, and to a lesser extent cis-
platin cytotoxicity, may be increased dramatically within the
area where the electric field has been applied. Therefore,
electrochemotherapy has a high therapeutic index, i.e., sig-
nificantly increased action on treated tumours and very lim-
ited side effects on normal tissues. Currently bleomycin is by
far the most utilized drug for electrochemotherapy
[8–10,12,13,15–18], and intravenous infusion is the most com-
mon administration of the drug [8,9,12,13].
Due to the dramatic increase in cytotoxicity, electroche-
motherapy is effective in all solid tumours, as reported so far;
melanoma, adenocarcinoma (breast or other), basal cell car-
cinoma, squamous cell carcinoma, sarcomas, and other solid
tumour malignancies. Electrochemotherapy is a local treat-
ment, and after drug administration the treatment area must
be uniformly covered by an adequate electric field, a consid-
eration similar to surgical approaches. Throughout the pub-
lished literature remarkably consistent responses have been
reported, with an approximately 80% OR (objective response
rate) including all tumour histologies, and approximately
60–70% CR (complete remission) rate after once-only treat-
ment [6,8,10,12,13,15–17,19,20]. These results were demon-
strated on tumours smaller than 3 cm in diameter after single
electrochemotherapy session, and although bigger tumours
have somewhat lower response rates, these remain high
[8,9,11,21]. Electrochemotherapy may be repeated, in case of
progression or in cases where tumour remains.
The basic mechanism of action is permeabilization of
tumour cells, allowing passage over the cell membrane and
thus a direct cytotoxic effect of bleomycin or cisplatin.
However there are also anti-vascular effects of electrochemo-
therapy which can contribute substantially, especially in well
vascularized tumours [10,22]. This effect is dual, as application
of electric pulses causes vasoconstriction, inducing drug
entrapment (termed the vascular lock), and thereafter vascular
disruption, due to the endothelial cell death in the tumour ves-
sels [23–25]. Furthermore, in line with tumour cell destruction
also local immune response may contribute to overall anti-
tumour effectiveness of electrochemotherapy [26–31].
Electrochemotherapy for internal tumours, such as liver,
pancreas and lung, is currently being investigated in a number
of clinical trials, but falls outside the scope of the current revi-
sion of the SOPs which pertain to the treatment of cutane-
ous tumours.
Electrochemotherapy is currently in use in many cancer
centres, and is used by dermatologists, surgeons, and oncolo-
gists, in agreement with national and international guidelines
for the treatment of metastases to the skin, and primary skin
cancer [1,2,32]. The current SOP update takes into account
the considerable experience gained, the expansion of indica-
tions due to the robustness of the technology, as well as the
diversity of patients treated with electrochemotherapy.
In order to produce the revised SOP we assembled
authors of the original SOP, along with a cross-disciplinary
team of dermatologists, plastic surgeons, head and neck
surgeons, general surgeons, and oncologists, all highly expe-
rienced in the use of electrochemotherapy for cutaneous
tumours, representing institutions across Europe. Below, all
important steps, from patient referral and indications over
treatment to follow-up are described.
Patient referral and indications for
electrochemotherapy
Patients should be referred after multidisciplinary team discus-
sion (MDT) and must be advised about treatment alternatives.
It must be evaluated whether, given the localization and extent
of tumour, the patient is likely to benefit from electrochemo-
therapy. The patients’ general condition and expected survival
should be weighed against the benefit expected from treat-
ment. Last but not least it is important to define the purpose of
the treatment together with the patient and to match his or
her expectations. Patients referred for electrochemotherapy
present with quite diverse clinical manifestations of cutaneous
metastases or primary skin tumours; from the patient with hun-
dreds of very small metastases, to patients with single or few
metastases and to patients with very large, ulcerated tumours.
Indications for treatment include:
 Cutaneous metastases, of any histology, which are symp-
tomatic due to bleeding, ulceration, oozing, odour,
or pain.
 Progression of cutaneous metastases, where development
of symptoms as listed above, is expected.
 Primary skin cancers, including recurrent tumours, where
other treatment modalities (surgery, radiotherapy, and
systemic therapies) have failed or are not possible.
 Patients who are receiving systemic therapy, but where
cutaneous metastases are progressing or not responding
despite satisfactory response to systemic therapy in
internal organs.
 Patient preference for electrochemotherapy, after other
treatment possibilities have been thoroughly explained to
the patient.
Contraindications
Pregnancy, lactation: Potentially fertile patients must use
adequate contraception.
Allergy or hypersensitivity to bleomycin or cisplatin:
Lifetime dose of bleomycin should not exceed 400,000
International Units (IU).
Pre-treatment examinations
Medical history and pre-treatment considerations
Medical history should be examined, and special attention
should be paid to the following:
 Previous problems with respect to local anaesthesia (lido-
caine) or general anaesthesia.
 Lung function (relevant when bleomycin administration
intravenously is planned): A pre-treatment lung diffusion
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capacity test is recommended only if the patient has
symptomatic pulmonary disease. For patients with benign
tumours (e.g., vascular malformations and keloids), a lung
diffusion capacity test should be performed before and
after treatment.
 Renal function: creatinine should be <150 mm/l to ensure
adequate renal clearance when using intravenous bleo-
mycin. In cases of low renal clearance, a lower adminis-
tered dose of bleomycin must be considered for
intravenous use, level of reduction according to institu-
tional or national guidelines. Furthermore intratumoural
administration can be a good alternative.
 Coagulation abnormalities do not preclude treatment, but
may be corrected to pre-surgery standards for the institu-
tion. Likewise medication decreasing coagulation is not a
contradiction, but may be handled according to usual
procedure for surgery.
 Liver disease does not preclude the use of
electrochemotherapy.
 Pre-treatment ECG analysis is needed as per anaesthetic
indications only.
 The presence of a pacemaker is not a contra-indication to
electrochemotherapy even in close proximity as long as
direct contact with the pacemaker is avoided. When treat-
ing close to a defibrillator it should be disconnected
before applying the pulses and reconnected immedi-
ately thereafter.
 Patients with pre-existing pain problems may experience
exacerbation after electrochemotherapy, and therefore
examination of need for improved pain control is recom-
mended before electrochemotherapy [33].
 Combination with other treatments. Progression in cuta-
neous metastases in patients who are experiencing stable
disease in internal organs on present anti-neoplastic treat-
ment is relatively common, possibly due to lower drug
concentrations in skin, in particular in hypo-perfused pre-
irradiated areas. In these cases electrochemotherapy may
be performed either concomitantly (as with endocrine
treatment), or allowing one week before, respectively one
day after electrochemotherapy spacing to other systemic
treatment (chemotherapy, targeted therapy), with
adequate thrombocyte and leukocyte function at the day
of electrochemotherapy. Combination with immunother-
apy is currently being investigated, in particular electro-
chemotherapy with check-point inhibitors [34,35].







Assessing size and number of tumours
The size of largest tumours and number of tumours must be
assessed to determine treatment strategy (Figure 1). With
very large tumours (exophytic more than 3 cm thick) consider
debulking the exophytic element within the electrochemo-
therapy session.
With current equipment, and using a 40min treatment
window, investigators have treated very large lesions up to
30 40 cm in extension in one session [9] and experience
reported by authors of this paper.
Documentation and imaging
Photographic documentation to document the size and loca-
tion of the tumours must be done before treatment as a
baseline in order to monitor treatment efficacy. A ruler
should be present in the photo and photos should always be
done in the same angle and perspective (Figure 2, [36]). A
recommendation would be to report sizes of e.g., up to
seven tumour nodules, including the largest, in order to have
a reasonable baseline assessment.
Other imaging modalities such as MRI, CT, PET for docu-
mentation of effect [37] (Figure 2), and ultrasound may be
used for guidance.
Patient information
Patients must be informed of expected outcomes of treat-
ment, as well as side-effects associated with treatment, both
in writing and oral communication. Topics covered must
include (1) a small risk of lung fibrosis associated with iv
bleomycin administration, (2) risk of post-procedure pain
(which may be counteracted by pain management plans, as
well as predicted before treatment), (3) expected duration
and nursing management plan for ulcerated lesions, (4) risk
of hyperpigmentation in the skin after use of bleomycin.
Treatment
Anaesthesia
Patients treated by electrochemotherapy need some form of
anaesthesia for the management and alleviation of symptoms
related to application of needle electrodes as well as the
electric pulse delivery. The regimen of anaesthesia is deter-
mined by the clinician/anaesthetist from the following
choices (Figure 1).
Figure 1. Deciding treatment strategy based on number and size of tumours to
be treated.
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Local anaesthesia. Local anaesthesia may be performed as a
rectangular infiltration of local anaesthetic around the area
to be treated, by injecting along four lines so that the nodule
is ‘fenced in’ by local anaesthetic. Be sure that an even
amount of anaesthetic is injected along all four sides of the
rectangle, so that pain transmission is completely blocked. Be
sure to include a margin around the area to be treated of
0.5–1 cm. If more than one nodule is to be treated, it is
necessary to consider the total amount of lidocaine: For
example, in a 70 kg patient the maximal dose without epi-
nephrine is 210mg (21ml of 1% lidocaine or 10.5ml of 2%
lidocaine) and with epinephrine 420mg (42ml of 1%
or 21ml of 2%). This will set the maximum of nodules treat-
able by one session with local anaesthesia, not surpassing
3mg/kg of lidocaine without epinephrine or 6mg/kg for lido-
caine with epinephrine. Another possibility is to use tumes-
cent local anaesthesia, where a higher volume of lower
concentration local anaesthesia is used to infiltrate the treat-
ment area [38].
If it is anticipated that there will be less than 0.5 cm from
the tip of the electrodes to periosteum, the option of local
anaesthesia should be reconsidered, since it may be difficult
to achieve suitable analgesia with local anaesthetic alone.
Another potential restriction to local anaesthesia is the local-
ization of the nodules in previously irradiated areas: experi-
ence has shown that is seems more difficult to apply local
anaesthesia in these previously irradiated areas and it is rec-
ommended to administer more lidocaine, as well as allow
more time for diffusion due to fibrosis in these tissues. Small
cutaneous tumours may be anaesthetized by local infiltration
of lidocaine just below the tumour, however, still covering
the area of electroporation. This may increase the number of
small nodules that can be treated with local anaesthetic in
one session.
Figure 2. Patients referred for electrochemotherapy present with different clinical stages of cutaneous metastasis. Evaluation of smaller tumours may favourably be
performed using digital photography and ruler (top panel, from [36]). For larger tumours, imaging such as PET/CT can be very valuable in determining response
(bottom panel, from [9]).
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Contractions of underlying musculature will appear in the
majority of treatments, due to a direct effect of the pulse.
The contraction can be alleviated by lifting the treatment
area up, using a gauze pad. It must be explained to the
patient that these brief contractions will occur.
Spinal anaesthesia or regional anaesthesia. Spinal anaes-
thesia may be considered for treatment of lower limbs, and
regional anaesthesia can be considered, when lesions to be
treated are confined to one limb.
Sedation. Premedication with sedatives is not necessary, and
many centres do not use it. There are, however, other centres
which feel that sedation in connection with local anaesthesia
works well [18].
General anaesthesia. General anaesthesia is performed in
accordance with guidelines and preferences of the treating
institution. Propofol sedation is a preferred choice because
the procedure is brief. Relaxation is performed in some
centres, in order to avoid contractions of underlying muscula-
ture, but many treating physicians feel that this is unneces-
sary. However, patients being treated on the upper thorax or
head and neck area need intubation in order to avoid muscle
contractions influencing the placement of e.g., a larynx-mask.
Before administering bleomycin FiO2 must be max 30% to
reduce risk of bleomycin associated lung toxicity. After anaes-
thesia, oxygen administration should be limited to 2 l/min.
These are precautions standardly used to reduce risk of tox-
icity, however this precaution must not be interpreted in a
way that the patient is not administered necessary oxygen in
case of need.
Drug administration
Bleomycin is either administered intratumourally or intraven-
ously. The potency of bleomycin is measured in units of anti-
microbial activity. One unit (U) contains 0.56–0.66mg of
bleomycin and 1 unit (U) is equivalent to 1000 international
units (IU) [39]. In Europe bleomycin is either dosed in mg or
International Units (IU), whereas Units (U) is the term used in
the US.
Intratumoural drug administration is recommended for
smaller and fewer tumours, whereas intravenous administra-
tion is preferable for multiple and larger tumours (Figure 1).
 Intravenous route: Measure patient height and weight in
order to calculate the body surface area (BSA).
Intravenous bleomycin is administered at a dose of
15,000 IU/m2 BSA, maximum dose capped at 30,000 IU
(corresponding to 2.0 m2 BSA), and modulation due to
high age and or compromised creatinine clearance may
be performed according to institutional guidelines.
Bleomycin is infused over short time (2–5min), and 8min
after the completion of infusion, the drug has diffused
into tumour tissues and the electric pulses can be applied.
A previous recommendation to end treatment at 20min
(equalling 28min after completion of bleomycin adminis-
tration) is now expanded to a treatment window of
40min, based on clinical experience. A recent pharmacoki-
netic study supports this [40]. It is even seen as possible
to continue administering pulses after this time window,
if deemed in the interest of the patient to hope for a
treatment effect which may indeed be present also after
the 40min window.
 Intratumoural route: Measure the lesions to calculate the
volumes and concentrations of bleomycin that will have
to be prepared (Figure 3). The recommended concentra-
tion of bleomycin injection solution is 1000 IU/ml.
Guidance for injection volumes are provided in Figure 3,
although injection can be performed by approximation
making sure the entire tumour volume is covered. The
upper limit for the bleomycin dose used intratumourally
is the dose that would be used if intravenously adminis-
trated. When using cisplatin the recommended mixture is
1mg/ml, and the recommended injection dose is to inject
to fill the tumour volume with drug.
Choice of electrode
Choose the appropriate electrode (the electric generator
must be able to adapt to various geometries in order to sup-
ply the correct field). If the tumour is less than 3 cm, consider
using parallel needle array electrodes. When larger areas
need to be covered consider using the hexagonal geometry
needle electrodes (Figure 4). Adjustable needle electrodes
(which can be either linear array or hexagonal geometry)
allow good support for the needles so that a depth up to
3 cm can be treated, and also so that needle length may be
adjusted to need. Finger electrodes can be convenient to use
for mucosal tumours as they are more flexible to work with.
Plate electrodes may be used for small superficial tumours. In
a few cases using more than one type of electrode may be a
good solution to cover the tumour correctly.
Figure 5 examplifies treatment procedure. After the pulses
are delivered the electrodes are repositioned in order to
Figure 3. Intratumoural treatment using bleomycin. Volumes for smaller tumours are relatively larger, to compensate for loss to the systemic circulation when the
injected volume is small.
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cover the whole tumour. The electric field drops off very
quickly outside the area of the electrodes, so the area to be
treated by pulses must be encompassed within the electro-
des. Therefore, not only must the appropriate electrode be
chosen, but the pattern of applications necessary to cover
the tumour volume must be decided as well. Overlap is rec-
ommended in the tumour tissue to ensure sufficient cover-
age. When treating large tumours adjacent to large vessels,
ultrasound guidance can be employed.
 The linear electrode may give better cosmetic results (due
to lower applied voltage as a function of smaller elec-
trode size), and is recommended when treating the
facial area.
 The hexagonal electrode will be able to cover
larger areas.
 Be sure to cover the entire treatment area with a margin.
 Avoid excessive treatment (too much overlap) in nor-
mal tissue.
Other considerations
Antibiotics: Administration of antibiotics is advised (choice of
antibiotic according to institutional guidelines) peri-opera-
tively, for patients with ulcerated lesions.
Pain management: The majority of patients have low pain
scores both before and after electrochemotherapy [33], but a
subset of patients experience more serious pain after treat-
ment. It has been shown that patients at risk for pain after
electrochemotherapy may be identified at the first visit by
predictors, of which the most important is a high pain score
before treatment, but also previous irradiation and large
tumours are predictors of post-procedure pain [33]. Figure 6
shows recommendations for pain management to be insti-
tuted at the pre-treatment visit.
Wound care and nursing considerations
 When treating with intravenous doses of bleomycin,
hyperpigmentation may occur in the skin where physical
pressure has been exerted. This includes marks from nee-
dle electrodes, but also skin stretching due to removal of
ECG-electrodes, surgical drapes, or pressure exerted due
to the position on the surgical bed may induce hyperpig-
mentation. Therefore, attention to positioning, and gentle
removal of tags and drapes after surgery is important.
Figure 5. Carrying out treatment. Electrochemotherapy is performed under
analgesia; for smaller tumours local anaesthesia (as indicated here) whereas
larger tumor conglomerates necessitate general anaesthesia. The chemothera-
peutic agent, bleomycin, is either injected locally (few, small tumours), or sys-
temically for large and/or many tumours. After drug administration the electric
pulses are administered through the electrodes that are inserted into the
tumour tissue. The electrodes are systematically moved, and pulses applied
again, in order to cover the entire tumour area. The pulsing sequence is very
brief, and therefore even large tumours may be covered in the course of a sin-
gle treatment because the procedure proceeds quickly.
Figure 4. Different electrodes suit different clinical challenges. Top left; linear
array electrode, ideal for smaller tumours. Due to the relatively lower applied
voltage (due to small electrode distance), ideal for treatment in local anaesthe-
sia. Hyperpigmentation using this electrode is very little to negligible, and this
electrode is thus recommended for use in the facial region. Top right; hex-
agonal electrode. This electrode should only be used under general anaesthesia,
and will often cause hyperpigmentation. The relatively larger area covered
allows larger tumours to be treated, making this electrode a good choice for
large cutaneous metastases, e.g., chest wall recurrence after breast cancer.
Middle left panel; plate electrodes, may be used for exophytic tumours. Middle
right panel; finger electrodes, may be used for mucosal tumours in e.g., the oral
cavity. Bottom; Adjustable electrodes allow better support for the needles, and
allows adjustment for tumours with heterogeneous size.
6 J. GEHL ET AL.
 Lesions can be covered with non-adherent dressings.
 For ulcerated lesions alginates, medical honey, silver or
charcoal may be applied underneath.
 Debridement of necrotic tissue, as treatment effects set
in, is important.
 There is no limitation in showering after treatment.
 In infected wounds consider using antibiotics.
 Pain management according to guidelines (Figure 6, [33]).
 Patients with cutaneous metastases often experience dis-
tress due to disfigurement, oozing and bleeding, as well
as the feeling of cancer stigmatisation. Thus special con-
sideration pertaining to the psychological challenges asso-
ciated with cutaneous metastases is important.
 Specific dedication and training for treatment of this
patient group is important.
Follow-up and retreatment
Follow-up is planned individually depending on patient
need. Follow-up schedule of two weeks (possibly nurse con-
sultation or telephone consultation), one month, two months,
four months and six months is frequently used as guideline.
Evaluation is done with measurement of tumour size and
documented with photography. For larger lesions longer
healing time will be necessary (Figure 2) and longer follow-
up and nursing may be necessary. Pain is managed based on
patient report of pain (Figure 6).
Patients can be retreated if the tumour is not sufficiently
treated at the first session or if recurrence appears within or
outside the treated area. It is suggested to discontinue if
lung diffusion capacity decreases with more than 25% from
baseline. There is no data regarding minimal interval
between retreatments, but at least four weeks is recom-
mended when using intravenous bleomycin. Maximum
therapeutic effect is seen after six to eight weeks.
For intratumoural drug application further treatments can be
applied whenever needed .
Access to information
In addition to the written information provided to the patient
at the first visit it is also recommended that information is
made available, e.g., at the hospital website, for care pro-
viders at home.
Use of electrochemotherapy in clinical practice
As electrochemotherapy is efficient with limited side effects
for cutaneous tumours, and treatment can be performed
over one or few sessions, the procedure is now increasingly
being used, and also introduced in to clinical guidelines. This
includes guidelines for advanced melanoma [41], and primary
squamous cell carcinoma [32], as well as guidance for
treatment of cutaneous metastases and primary skin
tumours [1,2].
Recent studies in respectively cutaneous and mucosal
tumours in the head and neck region [13,42], also based on
the treatment guidelines here described, have shown promis-
ing results with an overall response rate of 56% in previously
treated patients with recurrent mucosal head and neck can-
cer [42]. Specifically elaborated guidelines for this indication
may be anticipated.
Furthermore, electrochemotherapy is now being consid-
ered for a number of indications for tumours in internal
organs, in clinical trials.
The present updated SOP for the treatment of cutaneous
tumours is published to provide guidelines for the treatment
of primary and metastatic tumours of the skin, based on
Figure 6. Pain management plan. Most patients treated with electrochemotherapy only experience no or limited pain after treatment. A subset of patients do,
however, experience pain and these patients may be predicted from their pain score before treatment [33], i.e., at the pre-treatment visit. Based on patient pain
score (NRS¼ numeric rating scale, where 0 is no pain at all, and 10 is the worst pain imaginable), the patient may be assessed at the pre-treatment visit for a pain
management plan. Other factors that may forewarn higher risk of post-procedure pain are previous irradiation and large tumours [33].
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broad experience across treatment centres and medical
specialities.
Acknowledgments
This paper has been written solely by the authors.
Disclosure statement
JG is an inventor of patents (however not regarding the topics covered
in this paper) licensed to IGEA and has been invited to lecture at meet-
ings on electrochemotherapy by IGEA. LMM is an inventor of CNRS pat-
ents related to cliniporator equipment and has paid consultancy for
IGEA. CK received honoraria for lectures and was invited to meetings on
electrochemotherapy by IGEA. Travel cost for one meeting regarding this





[1] National Institute for Health and Care Excellence (NICE).
Electrochemotherapy for primary basal cell carcinoma and pri-
mary squamous cell carcinoma; [Internet] 2014. Available from:
www.nice.org.uk.
[2] National Institute for Health and Care Excellence (NICE).
Electrochemotherapy for metastases in the skin from tumours of
non-skin origin and melanoma; 2013. Available from: http://publi-
cationsniceorguk/electrochemotherapy-for-metastases-in-the-skin-
from-tumours-of-non-skin-origin-and-melanoma-ipg446.
[3] Kee S, Gehl J, Lee E. Clinical Aspects of Electroporation. New York
(NY): Springer; 2011.
[4] Belehradek M, Domenge C, Luboinski B, et al. Electro-
chemotherapy, a new antitumor treatment. First clinical phase I–II
trial. Cancer. 1993;72:3694–3700.
[5] Heller R, Jaroszeski MJ, Reintgen DS, et al. Treatment of cutane-
ous and subcutaneous tumors with electrochemotherapy using
intralesional bleomycin. Cancer. 1998;83:148–157.
[6] Marty M, Sersa G, Garbay JR, et al. Electrochemotherapy – an
easy, highly effective and safe treatment of cutaneous and sub-
cutaneous metastases: results of ESOPE (European Standard
Operating Procedures of Electrochemotherapy) study. Ejc
Supplements. 2006;4:3–13.
[7] Campana LG, Mocellin S, Basso M, et al. Bleomycin-based electro-
chemotherapy: clinical outcome from a single institution's experi-
ence with 52 patients. AnnSurgOncol. 2009;16:191–199.
[8] Matthiessen LW, Chalmers RL, Sainsbury DC, et al. Management
of cutaneous metastases using electrochemotherapy. Acta Oncol.
2011;50:621–629.
[9] Matthiessen LW, Johannesen HH, Hendel HW, et al.
Electrochemotherapy for large cutaneous recurrence of breast
cancer: a phase II clinical trial. Acta Oncol. 2012;51:713–721.
[10] Curatolo P, Quaglino P, Marenco F, et al. Electrochemotherapy in
the treatment of Kaposi sarcoma cutaneous lesions: a two-center
prospective phase II trial. Ann Surg Oncol. 2012;19:192–198.
[11] Campana LG, Valpione S, Mocellin S, et al. Electrochemotherapy
for disseminated superficial metastases from malignant melan-
oma. Br J Surg. 2012;99:821–830.
[12] Campana LG, Valpione S, Falci C, et al. The activity and safety of
electrochemotherapy in persistent chest wall recurrence from
breast cancer after mastectomy: a phase-II study. Breast Cancer
Res Treat. 2012;134:1169–1178.
[13] Bertino G, Sersa G, De Terlizzi F, et al. European research on electro-
chemotherapy in head and neck cancer (EURECA) project: results of
the treatment of skin cancer. Eur J Cancer. 2016;63:41–52.
[14] Mir LM, Gehl J, Sersa G, et al. Standard operating procedures of
the electrochemotherapy: Instructions for the use of bleomycin or
cisplatin administered either systemically or locally and electric
pulses delivered by the CliniporatorTM by means of invasive or
non-invasive electrodes. Eur J Cancer Suppl. 2006;4:14–25.
[15] Campana LG, Testori A, Mozzillo N, et al. Treatment of metastatic
melanoma with electrochemotherapy. J Surg Oncol. 2014;109:
301–307.
[16] Curatolo P, Miraglia E, Rotunno R, et al. Electrochemotherapy: a
valid treatment for Gorlin-Goltz syndrome. Acta Dermatovenerol
Croat. 2013;21:132–133.
[17] Quaglino P, Mortera C, Osella-Abate S, et al. Electrochemotherapy
with intravenous bleomycin in the local treatment of skin melan-
oma metastases. AnnSurgOncol. 2008;15:2215–2222.
[18] Campana LG, Testori A, Curatolo P, et al. Treatment efficacy with
electrochemotherapy: a multi-institutional prospective observa-
tional study on 376 patients with superficial tumors. Eur J Surg
Oncol. 2016;42:1914–1923.
[19] Spratt DE, Gordon Spratt EA, Wu S, et al. Efficacy of skin-directed
therapy for cutaneous metastases from advanced cancer: a meta-
analysis. J Clin Oncol. 2014;32:3144–3155.
[20] Kunte C, Letule V, Gehl J, et al. Electrochemotherapy in the treat-
ment of metastatic malignant melanoma: a prospective cohort
study by InspECT. Br J Dermatol. 2017;176:1475–1485.
[21] Whelan MC, Larkin JO, Collins CG, et al. Effective treatment of an
extensive recurrent breast cancer which was refractory to multi-
modal therapy by multiple applications of electrochemotherapy.
Eur J Cancer Suppl. 2006;4:32–34.
[22] Gehl J, Geertsen PF. Efficient palliation of haemorrhaging malig-
nant melanoma skin metastases by electrochemotherapy.
Melanoma Res. 2000;10:585–589.
[23] Gehl J, Skovsgaard T, Mir LM. Vascular reactions to in vivo electro-
poration: characterization and consequences for drug and gene
delivery. Biochim Biophys Acta. 2002;1569:51–58.
[24] Markelc B, Sersa G, Cemazar M. Differential mechanisms associ-
ated with vascular disrupting action of electrochemotherapy:
intravital microscopy on the level of single normal and tumor
blood vessels. PLoS One. 2013;8:e59557.
[25] Sersa G, Jarm T, Kotnik T, et al. Vascular disrupting action of elec-
troporation and electrochemotherapy with bleomycin in murine
sarcoma. Br J Cancer. 2008;98:388. 98:
[26] Andersen MH, Gehl J, Reker S, et al. Dynamic changes of specific
T cell responses to melanoma correlate with IL-2 administration.
Semin Cancer Biol. 2003;13:449–459.
[27] Calvet CY, Famin D, Andre FM, et al. Electrochemotherapy with
bleomycin induces hallmarks of immunogenic cell death in mur-
ine colon cancer cells. Oncoimmunology. 2014;3:e28131.
[28] Sersa G, Teissie J, Cemazar M, et al. Electrochemotherapy of
tumors as in situ vaccination boosted by immunogene electro-
transfer. Cancer Immunol Immunother. 2015;64:1315–1327.
[29] Mozzillo N, Simeone E, Benedetto L, et al. Assessing a novel
immuno-oncology-based combination therapy: ipilimumab plus
electrochemotherapy. Oncoimmunology. 2015;4:e1008842.
[30] Calvet CY, Mir LM. The promising alliance of anti-cancer electro-
chemotherapy with immunotherapy. Cancer Metastasis Rev.
2016;35:165–177.
[31] Falk H, Lambaa S, Johannesen HH, et al. Electrochemotherapy
and calcium electroporation inducing a systemic immune
response with local and distant remission of tumors in a patient
with malignant melanoma – a case report. Acta Oncol.
2017;56:1126–1131.
[32] Stratigos A, Garbe C, Lebbe C, et al. Diagnosis and treatment of inva-
sive squamous cell carcinoma of the skin: European consensus-
based interdisciplinary guideline. Eur J Cancer. 2015;51:1989–2007.
[33] Quaglino P, Matthiessen LW, Curatolo P, et al. Predicting patients
at risk for pain associated with electrochemotherapy. Acta Oncol.
2015;54:298–306.
8 J. GEHL ET AL.
[34] Queirolo P, Marincola F, Spagnolo F. Electrochemotherapy for the
management of melanoma skin metastasis: a review of the litera-
ture and possible combinations with immunotherapy. Arch
Dermatol Res. 2014;306:521–526.
[35] Heppt MV, Eigentler TK, Kahler KC, et al. Immune checkpoint
blockade with concurrent electrochemotherapy in advanced mel-
anoma: a retrospective multicenter analysis. Cancer Immunol
Immunother. 2016;65:951–959.
[36] Gehl J. [Investigational treatment of cancer using electrochemo-
therapy, electrochemoimmunotherapy and electro-gene transfer].
Ugeskr Laeger. 2005;167:3156–3159.
[37] Matthiessen LW, Johannesen HH, Skougaard K, et al. Dual time
point imaging fluorine-18 flourodeoxyglucose positron emission
tomography for evaluation of large loco-regional recurrences of
breast cancer treated with electrochemotherapy. Radiol Oncol.
2013;47:358–365.
[38] Kendler M, Micheluzzi M, Wetzig T, et al. Electrochemotherapy
under tumescent local anesthesia for the treatment of cutaneous
metastases. Dermatol Surg. 2013;39:1023–1032.
[39] Gothelf A, Mir LM, Gehl J. Electrochemotherapy: results of cancer
treatment using enhanced delivery of bleomycin by electropor-
ation. Cancer Treat Rev. 2003;29:371–387.
[40] Groselj A, Krzan M, Kosjek T, et al. Bleomycin pharmacokinetics of
bolus bleomycin dose in elderly cancer patients treated with electro-
chemotherapy. Cancer Chemother Pharmacol. 2016;77:939–947.
[41] Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of
melanoma. European consensus-based interdisciplinary guideline
– Update 2016. Eur J Cancer. 2016;63:201–217.
[42] Plaschke CC, Bertino G, McCaul JA, et al. European research on
electrochemotherapy in head and neck cancer (EURECA) project:
results from the treatment of mucosal cancers. Eur J Cancer.
2017;87:172–181.
ACTA ONCOLOGICA 9
